Weight loss injections at Nuffield Health: what you should know first

What the NICE guidance and trials say about these injections

The clinical case for GLP-1 weight-management injections is among the strongest in recent obesity medicine. SURMOUNT-1, published in the New England Journal of Medicine, randomised 2,539 adults with obesity and followed them for 72 weeks. At the 15mg tirzepatide dose, average body weight fell by around 20–21%. That is a meaningful clinical outcome, not a marginal shift. Semaglutide 2.4mg, studied in the STEP 1 trial, produced around 15% average weight loss over 68 weeks, also against placebo and lifestyle support.

NICE reviewed this body of evidence before publishing TA1026 in December 2024, recommending tirzepatide for adults in England with a BMI of 35 or above and at least one weight-related condition such as high blood pressure, dyslipidaemia, obstructive sleep apnoea, cardiovascular disease or type 2 diabetes. Lower BMI thresholds apply for South Asian, Chinese, Middle Eastern, Black African or African-Caribbean backgrounds under the same guidance. Private prescribers follow the licensed criteria from the medicines' SmPCs, which set the threshold at a BMI of 30 or above, or 27 or above alongside a weight-related condition, the prescriber assesses the full picture, not the number alone.

Both medicines are Black Triangle products, meaning the MHRA collects additional safety data as their real-world use grows. That is standard for newer medicines and is a transparency measure, not a warning sign.

How these injections work, and what the private prescribing route actually involves

Tirzepatide activates two gut-hormone receptors (GIP and GLP-1) simultaneously; semaglutide activates GLP-1 alone. Both slow how quickly the stomach empties, reduce appetite and help regulate blood sugar. Neither is a quick fix: the titration schedule starts low (tirzepatide begins at 2.5mg) to let your system adjust before doses are increased by the prescriber over subsequent months. Understanding that starting dose exists to reduce nausea rather than to produce weight loss is something a question our prescribers hear most weeks: patients sometimes worry the first pen isn't working when it is doing exactly what it should.

Any private provider (Nuffield Health or otherwise) must have a GPhC-registered prescriber review each case individually before issuing a prescription. At nume, every consultation is reviewed the same day by a named GPhC-registered Independent Prescriber, with photo-ID identity verification and live weight confirmation built into the process. There is no algorithm making the call. If you want to check any online pharmacy's standing, the GPhC pharmacy register lets you search by name or registration number and takes under a minute.

For a broader look at how these medicines compare to each other, the weight loss injections overview sets out the differences in mechanism, titration and trial results side by side.

Side effects to understand before you start

The most common side effects are gastrointestinal: nausea, loose stools, constipation, indigestion and, less commonly, vomiting. They tend to peak in the days after a new dose and settle as the body adjusts, though some people find them persistent enough to slow titration. Fatigue and headache are also reported, particularly early on.

More serious but rare effects include acute pancreatitis. The MHRA issued a Drug Safety Update in January 2026 specifically highlighting this risk for GLP-1 medicines: if you develop severe stomach pain that radiates to the back, seek urgent medical attention rather than waiting for a scheduled review. Gallbladder problems and signs of an allergic reaction are also on the prescriber's watch list.

Women taking oral contraceptives starting tirzepatide should use an additional non-oral method for the first four weeks of treatment and for four weeks after each dose increase, because gut-slowing can reduce pill absorption. NHS guidance does not flag the same interaction for semaglutide, but anyone on hormonal contraception should raise it at consultation. The same conversation applies to HRT: NHS England advises considering transdermal options while on tirzepatide.

Pregnancy, breastfeeding and actively trying to conceive are all situations where these medicines are not recommended. They are also not licensed for under-18s. If you are in any of these groups, discuss alternatives with your GP rather than seeking a private prescription. For questions specific to your situation, our support team can point you to the right clinical resource.

Choosing a provider: what to look for beyond the clinic name

Brand recognition is not the same as clinical rigour. Whether you're looking at Nuffield Health's weight management programme or a regulated online pharmacy, the checklist is the same. Does the service have a GPhC-registered prescriber reviewing each case? Is there identity and weight verification? Is there aftercare if you have a problem between appointments? And can you verify the pharmacy on the register?

Cost is a real consideration. UK private pricing for these injections has shifted significantly since Eli Lilly raised its list price in September 2025, typical private monthly costs now sit roughly in the £149–£375 range depending on dose and provider, as widely reported. Our cost and access guide walks through what those numbers typically include and what they sometimes don't. The short version: a lower headline price that excludes prescribing fees, aftercare and redelivery may not save money over the course of treatment. A longer short version: for a prescription medicine, price is the wrong measure to lead with.

People researching Nuffield Health specifically are usually asking whether the clinical quality justifies the cost and whether there is a faster or more accessible private alternative. Those are fair questions. For anyone outside a major city, or simply wanting clinical review without a face-to-face appointment, services in regions like Sheffield, Derby or Wakefield show how the same licensed medicines can be prescribed through different regulated routes. The medicine itself is identical; the service wrapper varies considerably. Speak to our prescribers to find out whether you are clinically suitable and what treatment would involve for you specifically.